Literature DB >> 26201425

Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis.

Feng Xu1, Hua He2, Wen Huang2, Yunting Lin2, Shiyu Luo2, Qian Du2, Ranhui Duan3.   

Abstract

OBJECTIVES: MicroRNA-200 family (miR-200f) has been consistently reported to be deregulated and modulate the metastatic process in multiple cancers. In the present study, we detected the expression of miR-200f in breast cancer (BC) tissue and explored its relationships with clinicopathological characteristics, especially with lymph node metastasis.
METHODS: Expression levels of miR-200a, miR-200b, miR-200c, miR-141, and miR-429 in 99 pairs of BC tissues and adjacent normal tissues were measured by real-time quantitative PCR. The correlation between miR-200f level and multiple clinicopathological factors was then examined by Mann-Whitney test, ANOVA, and operating characteristic (ROC) analysis.
RESULTS: All members of the miR-200f were down-regulated in BC tissue compared with that in normal adjacent tissue; miR-200a, miR-200b, and miR-200c were highly decreased (p < 0.05), while the differences of miR-141 and miR-429 between patients and the control group were not statistically significant. Furthermore, all five members were found to be distinctly decreased with the incidence of lymph node metastasis (p < 0.05); When the patients were divided into three groups according to the number of lymph node metastasis (0; 1-3; ≥4), a gradual decrease of miR-200f expression was observed with the increasing number of lymph node metastasis; ROC revealed that miR-200b can differentiate patients with lymph node metastasis from those without lymph node metastasis.
CONCLUSION: These observations imply that the down-regulation of miR-200f in human BC is associated with an invasive phenotype, and miR-200b may be useful to estimate the likelihood of the presence of pathologically positive lymph nodes.

Entities:  

Keywords:  Breast cancer; Clinicopathology; MicroRNA-200; Real-time quantitative PCR

Mesh:

Substances:

Year:  2015        PMID: 26201425     DOI: 10.1007/s12094-015-1364-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

Review 1.  Pathologic prognostic factors for patients with breast carcinoma. Which factors are important.

Authors:  N Weidner; B Cady; W H Goodson
Journal:  Surg Oncol Clin N Am       Date:  1997-07       Impact factor: 3.495

Review 2.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

Review 3.  A family of pleiotropically acting microRNAs in cancer progression, miR-200: potential cancer therapeutic targets.

Authors:  Hai-Feng Zhang; Li-Yan Xu; En-Min Li
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  MicroRNA-mediated breast cancer metastasis: from primary site to distant organs.

Authors:  L Wang; J Wang
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

Review 5.  Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis.

Authors:  Ming Shi; Dan Liu; Huijun Duan; Beifen Shen; Ning Guo
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

6.  The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.

Authors:  Manav Korpal; Esther S Lee; Guohong Hu; Yibin Kang
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

Review 7.  Breast cancer as a systemic disease: a view of metastasis.

Authors:  A J Redig; S S McAllister
Journal:  J Intern Med       Date:  2013-08       Impact factor: 8.989

8.  miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family.

Authors:  Feng Ye; Hailin Tang; Qing Liu; Xinhua Xie; Minqing Wu; Xiaoping Liu; Bo Chen; Xiaoming Xie
Journal:  J Transl Med       Date:  2014-01-21       Impact factor: 5.531

9.  Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer.

Authors:  Marie Tuomarila; Kaisa Luostari; Ylermi Soini; Vesa Kataja; Veli-Matti Kosma; Arto Mannermaa
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

10.  Members of the miRNA-200 family regulate olfactory neurogenesis.

Authors:  Philip S Choi; Lisa Zakhary; Wen-Yee Choi; Sophie Caron; Ezequiel Alvarez-Saavedra; Eric A Miska; Mike McManus; Brian Harfe; Antonio J Giraldez; H Robert Horvitz; Alexander F Schier; Catherine Dulac
Journal:  Neuron       Date:  2008-01-10       Impact factor: 17.173

View more
  15 in total

Review 1.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

2.  Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.

Authors:  Patsy S Soon; Pamela J Provan; Edward Kim; Nirmala Pathmanathan; Dinny Graham; Christine L Clarke; Rosemary L Balleine
Journal:  Clin Exp Metastasis       Date:  2017-12-06       Impact factor: 5.150

3.  MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer.

Authors:  Guangxin Zhang; Wei Zhang; Bingjin Li; Erica Stringer-Reasor; Chengjing Chu; Liyan Sun; Sejong Bae; Dongquan Chen; Shi Wei; Kenneth Jiao; Wei-Hsiung Yang; Ranji Cui; Runhua Liu; Lizhong Wang
Journal:  Breast Cancer Res       Date:  2017-06-21       Impact factor: 6.466

4.  Microarray profiling of circular RNAs in human papillary thyroid carcinoma.

Authors:  Nianchun Peng; Lixin Shi; Qiao Zhang; Ying Hu; Nanpeng Wang; Hui Ye
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

5.  Downregulation of hsa_circ_0011946 suppresses the migration and invasion of the breast cancer cell line MCF-7 by targeting RFC3.

Authors:  Juan Zhou; Wen-Wen Zhang; Fang Peng; Jia-Yuan Sun; Zhen-Yu He; San-Gang Wu
Journal:  Cancer Manag Res       Date:  2018-03-19       Impact factor: 3.989

6.  Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients.

Authors:  Zhuo Li; Yue-Yun Ma; Juan Wang; Xian-Fei Zeng; Rui Li; Wei Kang; Xiao-Ke Hao
Journal:  Onco Targets Ther       Date:  2015-12-31       Impact factor: 4.147

7.  Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma.

Authors:  Julia Liep; Ergin Kilic; Hellmuth A Meyer; Jonas Busch; Klaus Jung; Anja Rabien
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

Review 8.  Decoding the usefulness of non-coding RNAs as breast cancer markers.

Authors:  Maria Amorim; Sofia Salta; Rui Henrique; Carmen Jerónimo
Journal:  J Transl Med       Date:  2016-09-15       Impact factor: 5.531

9.  A qRT-PCR and Gene Functional Enrichment Study Focused on Downregulation of miR-141-3p in Hepatocellular Carcinoma and Its Clinicopathological Significance.

Authors:  Cui-Zhen Liu; Zhi-Hua Ye; Jie Ma; Rong-Quan He; Hai-Wei Liang; Zhi-Gang Peng; Gang Chen
Journal:  Technol Cancer Res Treat       Date:  2017-04-23

10.  The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells.

Authors:  Dengfeng Li; Hong Wang; Hongming Song; Hui Xu; Bingkun Zhao; Chenyang Wu; Jiashu Hu; Tianqi Wu; Dan Xie; Junyong Zhao; Qiang Shen; Lin Fang
Journal:  Oncotarget       Date:  2017-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.